TMS for Depression: Evidence, Eligibility, and Treatment Process
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Transcranial magnetic stimulation (TMS) is an evidence-based, noninvasive medical treatment for major depressive disorder, especially when appropriate first treatments have provided insufficient relief or have been difficult to tolerate. A magnetic coil positioned against the scalp generates brief magnetic pulses that induce electrical activity in targeted cortical networks. Treatment usually takes place in an outpatient office while the patient is awake; a standard course commonly involves weekday sessions over four to six weeks. National Institute of Mental Health · CANMAT clinical guideline.
The central questions are whether a person has a depressive condition for which TMS is appropriate, which stimulation protocol is being proposed, how strong the evidence is for that protocol, what risks and practical burdens apply, and how improvement will be measured. Established protocols offer a meaningful chance of improvement, but outcomes vary. A qualified clinician should evaluate diagnosis, safety, previous treatment, current medications, other conditions, and patient preferences before recommending treatment. 2025 multidisciplinary consensus.
This article focuses on TMS used for unipolar major depression. The clinical overview and diagnostic route appear in Depression Diagnosis: What a Clinical Evaluation Includes. TMS protocols for obsessive-compulsive disorder have distinct indications and research and are addressed in TMS for OCD.
I. What Is TMS for Depression?
Repetitive transcranial magnetic stimulation (rTMS) delivers a series of magnetic pulses from a coil placed over a selected part of the head. Each pulse creates a changing magnetic field that induces a small electrical current in brain tissue. Repeated stimulation can alter activity and connectivity in neural circuits involved in attention, emotion regulation, and cognitive control. The most extensively studied depression target is the dorsolateral prefrontal cortex (DLPFC). Clinicians use defined stimulation settings rather than an undirected application of magnetism. FDA device guidance · 2025 consensus.
The term TMS may describe a single-pulse research procedure, repetitive clinical stimulation, deep TMS using differently designed coils, and patterned stimulation such as theta-burst stimulation. Clinical evidence is specific to the device, site, pulse pattern, dose, number of sessions, and patient population. A protocol that works for one condition cannot be assumed to work for another. FDA clearance applies to particular devices and labeled indications; it is not a blanket certification of every technique advertised under the TMS name.
TMS differs from electroconvulsive therapy (ECT). Conventional depression-focused rTMS does not intentionally induce a therapeutic seizure, does not ordinarily require general anesthesia or a muscle relaxant, and generally allows a patient to resume routine activities after an appointment. ECT intentionally produces a medically controlled seizure under anesthesia and may be particularly important in certain severe or urgent presentations. Choice depends on clinical need rather than a universal ranking. NIMH brain stimulation overview · CANMAT.
1. Does TMS change the brain permanently?
An acute course is intended to produce neurophysiological changes beyond the minutes of active stimulation, and clinical improvement may persist after appointments stop. The durability of an individual's response cannot be predicted from a scan or a single session. Longer-term maintenance, recurrence prevention, and repeat-course decisions require follow-up, because depressive disorders can recur and TMS does not erase every biological or psychosocial factor involved. 2025 consensus.
2. Is it magnetic therapy or brain surgery?
TMS is a prescribed clinical neuromodulation treatment delivered by a trained team with regulated equipment, individualized dosing, and safety procedures. It involves no implanted electrode, incision, or operation. It should be distinguished from consumer magnet products and from transcranial direct-current stimulation (tDCS), which uses a different physical method and evidence base.
II. Who May Be Eligible for TMS?
The usual candidate is a person with a clinician-confirmed current episode of major depressive disorder who continues to experience meaningful symptoms despite an appropriate treatment plan, or who cannot tolerate certain standard treatments. A clinician assesses past medication trials, adequacy of dose and duration, response to psychological treatment, current symptom severity, functional impairment, medical history, and the burden of repeated visits. Guidelines recognize rTMS as an evidence-supported option in difficult-to-treat depression; access and insurer criteria often affect when it is offered. CANMAT · VA/DoD major depressive disorder guideline.
Treatment-resistant depression is a clinical description of insufficient benefit after an adequate treatment history, often operationalized for research as failure of at least two appropriate antidepressant trials. The number two alone does not establish a universal diagnosis or automatic TMS eligibility. A prescribed trial may have been stopped too early, taken inconsistently, limited by intolerable effects, or used for a misclassified illness. Clinical definitions, device labeling, guidelines, and insurance policies may differ. These distinctions should be resolved during evaluation, with the treatment record carefully documented.
Some patients may reasonably consider TMS earlier because of prior good response, substantial medication intolerance, informed preference, or other factors. The clinician must still weigh safety, evidence, alternative treatments, clinical urgency, and resources. The fact that a person is unhappy with a medication does not automatically establish treatment resistance; the fact that two medications were unsuccessful does not guarantee that a payer will authorize stimulation. CANMAT recommendations on neuromodulation.
1. Diagnosis must be confirmed first
Depressed mood, loss of interest, low energy, an elevated questionnaire score, and the popular phrases “smiling depression” or “high-functioning depression” are not substitutes for a clinical diagnosis. A major depressive episode describes an episode of symptoms; major depressive disorder refers to a diagnosis determined through history and exclusion of certain alternative explanations. Persistent depressive disorder and depressive symptoms caused by another health condition can call for different management. See the Hub's clinical depression diagnosis guide and the NIMH depression guide.
2. Bipolar disorder must be considered
A history of mania, hypomania, decreased need for sleep with increased energy, unusually elevated or irritable mood, racing thoughts, or previous antidepressant-associated activation requires careful assessment before applying a unipolar depression protocol. Bipolar depression belongs to a different clinical treatment pathway. TMS-associated hypomanic or manic switches have been reported; bipolar illness is therefore relevant even when a person currently reports only low mood. Mixed features also affect risk evaluation. 2025 TMS consensus · CANMAT.
3. Is TMS suitable during an immediate psychiatric crisis?
A person with escalating suicidal intent, inability to maintain basic safety, profound self-neglect, catatonia, or depression with severe psychotic symptoms may need urgent, closely supervised care. A multiweek outpatient TMS schedule is not a substitute for immediate crisis assessment. ECT or another setting and treatment may be preferred when rapid intervention is clinically critical. The care team should assess suicidality throughout any TMS course, and someone in imminent danger should contact local emergency services. In the United States, call or text 988 for crisis support. FDA safety guidance · CANMAT.
III. Contraindications, Precautions, and Clinical Safety Screening
A TMS assessment begins with a detailed implanted-device and metal screening. Certain ferromagnetic or conductive objects in or near the treatment field, and certain implanted electronic devices and leads, can present serious hazards. Examples include particular cochlear implants, brain stimulation devices, intracranial electrodes, some aneurysm clips or coils, and metallic fragments. The actual risk depends on material, location, model, device instructions, and distance from the coil. Medical implants elsewhere in the body also require disclosure so the clinic can apply the specific equipment instructions. FDA special-controls guidance.
Dental fillings and many other common materials do not automatically exclude every patient. Never self-clear an implant based on an online list: the clinic should obtain exact device documentation and assess compatibility using the manufacturer's current labeling. Anyone with metallic fragments following an accident or prior cranial surgery should tell the prescribing team before treatment.
A seizure history, epilepsy, brain injury, neurological disease, medicines that may lower seizure threshold, recent medication changes, significant sleep deprivation, heavy alcohol intake, or abrupt withdrawal from alcohol or sedative medicines can influence seizure risk and require individual assessment. A history of fainting, severe anxiety about stimulation, current hearing difficulties, pregnancy, and other medical circumstances also deserve discussion. The team may recommend further specialist input or change the protocol. 2025 consensus.
1. What about pregnancy and implanted cardiac devices?
Evidence and safety considerations vary by patient, device, stage of pregnancy, and treatment configuration. A patient should disclose pregnancy or plans for pregnancy before treatment; an individualized discussion should address what is known, what remains uncertain, and available alternatives. Pacemakers or other electronic implants require explicit verification of compatibility and monitoring plans. A generic assurance that “TMS is safe for everyone because it is magnetic” is clinically unsound.
2. What about teenagers and older adults?
Age matters, and labeling changes over time. An FDA 510(k) clearance for the NeuroStar Advanced Therapy System includes an adjunctive major-depression indication for adolescents aged 15–21; this is specific to that device and use and is not a universal authorization for all TMS equipment or all pediatric depressive conditions. Care of adolescents requires specialty assessment, developmental considerations, family participation as appropriate, careful benefit–risk evaluation, and coordination with existing treatment. FDA K231926 indications for use.
Older adults may receive TMS after assessment of cognition, comorbidities, medication use, fall risk, transport, and ability to follow a treatment schedule. Age by itself is not a complete predictor of response. Late-life depression may also raise questions about neurological illness, medical contributors, and treatment burden. CANMAT guideline.
IV. How Effective Is TMS for Depression?
Multiple randomized sham-controlled clinical trials, systematic reviews, and practice guidelines support the antidepressant effect of established rTMS protocols for selected patients. Active stimulation outperforms sham on important measures in major depression, while not everyone responds and some individuals improve with sham treatment as well. Study samples, severity, prior treatment exposure, coil technology, protocol, and the definition of an outcome account for some variation. O'Reardon et al. randomized trial · 2025 consensus review.
A clinically meaningful response commonly means a substantial reduction in depressive symptom scores, often at least 50% from baseline in research. Remission usually means symptoms have fallen below a specified threshold, which is a more demanding outcome. Functional recovery, return to valued activities, and lasting improvement also matter. Response, remission, subjective relief, and permanent cure are different outcomes; published percentages cannot be transferred to a particular person without considering the underlying study.
In the CANMAT 2023 guideline update, conventional rTMS for difficult-to-treat depression is discussed with approximate response rates of 40–50% across relevant studies. A large real-world registry reported higher and widely varying response and remission estimates depending on whether patient-rated or clinician-rated measures were used and how the sample was defined. Open-label observational outcomes must not be interpreted as placebo-controlled causal effect sizes. CANMAT · Sackeim et al. 2020 registry.
1. Why does a clinic's “success rate” vary?
Some advertisements combine improved scores, partial response, full remission, and patient satisfaction under the word success. They may report only patients who completed all sessions or use a different assessment scale. Ask a provider for its denominator, treatment-resistant case mix, protocol, follow-up period, outcome definition, independent verification, and how many people discontinued. A high single-clinic number is not equivalent to a randomized controlled treatment effect.
2. When does improvement occur?
Some people notice changes during the first several weeks, while others improve later in the course or after it finishes. A lack of improvement in the first handful of appointments is not by itself proof of failure. The team should monitor symptoms and functioning repeatedly, review missed sessions and medications, and reassess the plan when progress is limited. Statements promising rapid or universal recovery exceed the available evidence. NIMH treatment overview · 2025 consensus.
V. Types of TMS: Standard rTMS, Theta Burst, Deep TMS, and Accelerated Protocols
The name TMS describes a family of stimulation strategies. Frequency, pulse count, intensity, coil and brain target influence how treatment is delivered. Evidence is strongest for several established clinical protocols and less mature for particular accelerated, image-guided or experimental variations. A shorter appointment may be valuable, but it does not necessarily mean a stronger or more durable treatment.
1. Standard high-frequency or low-frequency rTMS
One established approach uses high-frequency stimulation of the left DLPFC. Another uses low-frequency stimulation of the right DLPFC. Bilateral approaches stimulate both hemispheres in sequence. Guidelines differentiate the evidence and clinical suitability of each protocol; selection may depend on prior response, tolerability, availability, and clinical circumstances. Some conventional stimulation sessions take about 20–40 minutes, depending on the device and settings. CANMAT protocol table and commentary.
2. Intermittent theta-burst stimulation (iTBS)
Theta-burst stimulation uses patterned bursts of pulses, enabling short stimulation sessions. In the 414-participant THREE-D randomized noninferiority trial, intermittent theta-burst treatment lasting approximately three minutes was noninferior to a much longer standard high-frequency rTMS session on depressive-symptom reduction under that study's protocol. The course still involved repeated weekday visits. Shorter delivery duration should be distinguished from reduced total calendar time. Blumberger et al., Lancet 2018.
A 2024 systematic review and network meta-analysis of 23 randomized controlled trials assessed several theta-burst protocols, identifying favorable evidence for left-sided iTBS and selected bilateral approaches. It also illustrates why the label theta burst should not be treated as one uniform treatment with a single efficacy rate. Kishi et al., Molecular Psychiatry.
3. Deep TMS (dTMS)
Deep TMS uses coil configurations designed to stimulate a broader or deeper cortical volume than some conventional figure-eight coils. The name does not mean that an electrode is implanted or that any deep-brain region can be selected freely. Device indications and treatment protocols differ, and tolerability and seizure-risk estimates must be interpreted with the appropriate coil design and population. Claims that deeper stimulation automatically makes treatment superior are not established by the name itself. 2025 consensus.
4. Accelerated TMS and Stanford Neuromodulation Therapy
Accelerated protocols give multiple sessions per day, shortening the number of treatment days. One personalized, high-dose approach associated with Stanford Neuromodulation Therapy (SNT) combines frequent iTBS sessions with individualized targeting. A randomized, sham-controlled 2026 report enrolled 53 people with treatment-resistant depression and randomized 48 who met entry criteria, providing additional evidence alongside earlier trials. These results are clinically important but do not mean that every accelerated package sold by a clinic is equivalent to that studied procedure. Kratter et al., World Psychiatry 2026.
A July 2026 systematic review and meta-analysis pooled 15 sham-controlled randomized trials totaling 704 participants with major depressive episodes, including trials of both unipolar and bipolar presentations. Accelerated iTBS outperformed sham for symptom reduction and showed higher pooled response and remission, while protocols varied substantially. The pooled response risk ratio was 1.99; the pooled remission risk ratio was 1.77. These are relative comparisons, not claims that 99% or 77% of recipients improve. More research is needed to establish optimal dosing, individual targeting, durability, and generalizability. Santos et al., Brain Stimulation 2026.
VI. What Happens Before the First TMS Session?
The first step is a consultation with a clinician qualified to evaluate major depression and prescribe or supervise stimulation. The assessment may include a diagnostic interview, history of prior depressive and possible hypomanic or manic episodes, suicide-risk evaluation, medical and neurological review, implanted-device questions, medication and substance history, and discussion of current psychotherapy. Symptom questionnaires can help establish a baseline and monitor progress, but they do not independently determine the diagnosis. 2025 consensus · NIMH depression.
Bring a complete medication list, past antidepressant names, approximate doses and durations, the reasons each treatment stopped, prior psychotherapy details, known medical implants, past seizures or brain injuries, and relevant contact information for current clinicians. If insurance is involved, the office may request records to establish medical necessity. Ask how contraindications are screened, which protocol is proposed, what outcome measures will be used, who will supervise treatment, and what happens if symptoms worsen.
1. Mapping and motor threshold
For many protocols, an early appointment establishes the stimulation location and motor threshold: the stimulation strength required to produce a small movement, often in a hand muscle, under specified conditions. The treatment intensity may then be prescribed relative to that threshold. Some systems use scalp measurements and others use neuronavigation. Reassessment may be required as treatment proceeds or when the patient's circumstances change. Mayo Clinic procedure description.
2. Treatment planning and informed consent
A reasonable consent discussion covers the expected number and duration of visits, evidence behind the recommended protocol, common discomfort, rare serious risks, alternative options, costs, attendance demands, confidentiality, how adverse events are handled, and the plan for monitoring symptoms and safety. The clinic should describe which aspects are established practice and which are experimental or newly adopted.
VII. What Happens During a TMS Appointment?
The patient generally sits in a reclining or supported chair. Staff position a coil near the treatment target, provide hearing protection, verify relevant safety information, and begin a series of magnetic pulses according to the prescription. The pulses cause audible clicks and may feel like tapping or mild knocking on the scalp. Forehead or facial muscle contractions may occur. Staff should ask about discomfort and adjust within safe protocol limits. NIMH · Mayo Clinic.
A standard course often schedules five visits per week for approximately four to six weeks, sometimes with additional tapering sessions or other clinic-specific plans. Active pulse delivery may take only a few minutes for some iTBS protocols, while traditional protocols take substantially longer. Total appointment length also includes positioning, symptom checks, and preparation. Accelerated schedules are very different and should be explained individually.
Routine clinical TMS does not require anesthesia or sedation, and people commonly return to their activities afterward. If a patient feels faint, has significant discomfort, experiences a seizure, or has other concerning symptoms, the team must manage the event and reassess treatment. Hearing protection and adherence to safety procedures are part of the treatment, not optional extras.
1. Can I drive or go to work afterward?
Many patients can drive and work after conventional outpatient TMS because it usually does not involve sedative anesthesia. An individual who feels dizzy, unwell, or otherwise impaired should be assessed before leaving or driving. Follow the treating clinic's advice, especially when other medical conditions or treatments are involved.
2. Are appointments painful?
Patients commonly describe tapping, scalp sensitivity, a headache, or facial muscle twitching rather than severe pain. Tolerance varies; the first sessions may be more uncomfortable. Staff should invite honest reporting and use appropriate adjustments rather than insisting that every patient must tolerate the same sensation. THREE-D randomized trial.
VIII. Side Effects and Rare Serious Risks
The most common adverse effects are temporary scalp discomfort, headache, and local muscle twitching. Some people describe lightheadedness, fatigue, or transient anxiety surrounding appointments. Intensity and discomfort may differ by protocol. Most adverse effects in trials are mild to moderate, but tolerability should be monitored throughout care. 2025 consensus · THREE-D trial.
A seizure is an uncommon but medically important risk. Published estimates for ordinary clinical protocols have generally been below 0.1%, with different reports and coil types yielding different frequencies per treatment or per patient. Estimates such as one event in approximately 33,000 sessions describe specific datasets and should not be presented as an individualized guarantee. Seizure history, stimulation settings, alcohol use, withdrawal, medications, and sleep loss can affect risk. The treatment setting should have appropriately trained personnel and an emergency response plan. 2025 international consensus review · FDA guidance.
Because stimulation produces loud clicking sounds, proper ear protection is essential. Induced hypomania or mania is rare but should be considered when mood and energy change substantially, particularly in people with bipolar vulnerability. Worsening depression and new suicidal thoughts require timely evaluation and an appropriate clinical response; they must never be dismissed as normal signs that the treatment is working. 2025 consensus.
1. Does TMS cause memory loss?
Unlike ECT, established rTMS treatment has generally not shown the pattern of significant adverse cognitive effects associated with seizure-based treatment. This does not mean every person will notice cognitive improvement, nor does it eliminate the need to investigate new cognitive symptoms. Depression itself can affect concentration and memory. CANMAT.
2. Can TMS make depression worse?
Clinical deterioration can occur during any depression treatment course, whether because of the disorder's course, an inadequate response, comorbidity, or adverse effects. Monitoring is therefore essential. Notify the clinician promptly about increased agitation, unusual energy with little sleep, profound mood worsening, suicidal thoughts, or other important changes. FDA guidance.
IX. TMS Compared With Antidepressants, Psychotherapy, ECT, and Ketamine
Antidepressants and evidence-based psychotherapies remain important initial treatments for many people with major depression. TMS can become an additional option when the response is inadequate, adverse medication effects are burdensome, or clinical history favors neuromodulation. Medication, psychotherapy, and TMS may be used together under a coordinated plan. TMS has a different adverse-effect profile from systemic medication, but treatment requires equipment, trained personnel, frequent attendance, and careful supervision. CANMAT guideline.
ECT has evidence and an important role in severe, psychotic, catatonic, or urgent depressive illness; it uses anesthesia and seizure induction and has different cognitive and procedural risks. TMS generally offers a less intensive outpatient approach for appropriately selected patients. These are different clinical tools, and the choice should reflect severity, urgency, response history, medical risk, and informed preference rather than marketing comparisons. NIMH · CANMAT.
Ketamine and esketamine involve pharmacological approaches with specific monitoring and indication requirements. Their speed of action, eligibility, administration, adverse effects, access, and evidence cannot be inferred from TMS research. Direct comparisons across therapies are complicated by different enrolled populations and study designs. Depression treatment decisions should use individualized evaluation, not an uncontrolled ranking of advertised remission percentages.
Coexisting anxiety may complicate symptom tracking and treatment selection. The Hub explains that relationship separately in Anxiety and Depression: Why They Commonly Co-Occur. Other clinical conditions also require their own evidence-based assessment.
X. How Are Treatment Response and Remission Measured?
The clinic should document the initial symptom pattern, severity, functioning, safety, and the patient's own meaningful goals before treatment starts. Standardized scales may be repeated during and after the course to quantify change, but decisions should integrate clinical interview, sleep, daily functioning, adverse effects, medication changes, and contextual factors. A score that improves while functioning deteriorates calls for further assessment. CANMAT.
A response is commonly operationalized as a large proportional decrease in symptom severity. Remission indicates few enough symptoms to meet a predefined threshold; clinical recovery additionally concerns sustained functioning and quality of life. A person can have an important partial benefit without reaching remission. Conversely, one low score at a single appointment is not proof of lasting recovery.
Assessments should continue near the end of treatment and during follow-up. If benefits fade, the clinician can re-examine stressors, physical conditions, adherence to ongoing treatment, medication and psychotherapy options, and whether another TMS course or a different intervention has an evidence-supported role.
XI. How Long Do TMS Benefits Last, and Can Treatment Be Repeated?
TMS can produce improvement that persists beyond the end of the acute course, although some patients experience residual symptoms, relapse, or recurrence. The expected duration varies, and robust evidence for a single universal maintenance schedule is lacking. Clinical follow-up and relapse-prevention planning remain necessary. Continued psychotherapy or medication may be appropriate depending on the treatment history, symptoms, preferences, and clinical guidelines. 2025 TMS consensus.
Repeat treatment may be considered after a clinically meaningful prior response followed by return of symptoms, particularly when the original course was tolerated. Maintenance or booster schedules should be explained in terms of evidence, cost, frequency, and goals. An insurer's decision to cover retreatment may depend on documented earlier improvement and interval requirements.
XII. What If TMS Does Not Work?
Nonresponse is a signal to reevaluate the whole clinical picture rather than to assume that the patient has an incurable condition. Questions include whether the original diagnosis remains accurate, whether bipolarity or other conditions were missed, whether stimulation parameters and course length were appropriate, whether medications or sleep changed, and whether the chosen outcome measure captured the patient's actual problems. CANMAT guidance on inadequate response.
After review, the treatment team may discuss adjustment of the depression treatment plan, another psychotherapy or medication strategy, ECT, ketamine/esketamine when appropriate, or specialized consultation. Switching to an experimental TMS protocol should involve explicit discussion of the limits of its evidence. Patients should receive a practical follow-up plan even when the acute course produces little improvement.
XIII. Insurance Coverage, Cost, and Access in the United States
The total cost depends on the number of sessions, stimulation type, clinic, and negotiated prices; dollar figures presented without a location, date, protocol, and billing assumptions are unreliable. Many American plans and some Medicare contractors cover particular depression TMS procedures under defined medical-necessity requirements. Criteria can include a confirmed diagnosis, adequate unsuccessful treatments, contraindication screening, and documentation by an eligible practitioner. Rules differ across payers, policies, and Medicare contractor regions. CMS local coverage determination example.
Before starting, request a written estimate describing mapping fees, the number of sessions, follow-up appointments, any accelerated-protocol charges, insurance authorization, deductible, coinsurance, and whether the proposed exact code and device protocol are covered. Also ask whether a shortened schedule is reimbursed at the same rate as standard treatment. Travel and lost-work costs may matter as much as the billed procedure.
FDA clearance concerns a device's authorized marketed use; it does not require an insurer to pay for a treatment. Likewise, insurance approval is not proof that a protocol is better than other evidence-based options. A clinic should explain the differences clearly.
XIV. How to Choose a Qualified TMS Clinic
The essential questions concern clinical oversight, accurate diagnosis, protocol-specific evidence, staff training, safety, documentation, and continuity of care. Ask who prescribes TMS, how the motor threshold and target are determined, how seizures and other emergencies are handled, what equipment is used, whether the offered protocol fits the device's labeled indications, and how outcomes are recorded. 2025 international consensus.
A quality clinic should explain the probability and limits of benefit, discuss risks in comprehensible language, welcome coordination with existing clinicians, and set expectations for a full treatment course. It should also offer a clear plan when benefit is incomplete and a pathway for urgent assessment if mood or safety deteriorates.
1. Questions to bring to the consultation
Ask: What diagnosis and clinical evidence support TMS in my situation? Which exact protocol, coil, device, and stimulation target do you propose? Is it FDA-cleared for my particular indication and age? Which risk factors and implants need review? How many visits are planned and how will symptoms be measured? What is the realistic chance of response versus remission in patients comparable to me? What will happen if I have adverse effects, miss visits, become more depressed, or fail to respond? What will insurance pay, and what are my likely out-of-pocket costs?
XV. Frequently Asked Questions
1. Is TMS FDA-approved for depression?
Specific rTMS systems have received U.S. FDA clearance for depression indications, beginning in 2008. More recent clearances concern additional devices, protocols, or groups. The regulatory terminology for many TMS devices is 510(k) clearance rather than a pharmaceutical-style approval. Verify the exact equipment and its currently labeled use. FDA guidance.
2. How many TMS sessions will I need?
Traditional courses often involve weekday visits over four to six weeks, with the specific number depending on the prescription. Some accelerated protocols use multiple daily sessions over fewer days. Three-minute iTBS pulse delivery should not be confused with completion of a treatment course in three minutes. NIMH.
3. Can TMS be used while taking antidepressants?
Often yes. Research and clinical practice frequently include people continuing stable prescribed medications during TMS. Do not discontinue or change psychiatric medication on your own to qualify for stimulation. Discuss all medications with the treating team because some may influence seizure threshold, tolerability, or interpretation of the response. CANMAT.
4. Is TMS a cure for treatment-resistant depression?
It is a treatment with clinically meaningful evidence of benefit for some people whose earlier therapies did not provide sufficient improvement. Response does not guarantee remission, and remission does not guarantee that depression cannot recur. Subsequent care and monitoring remain essential. 2025 consensus.
5. How does TMS differ from electroshock treatment?
The common informal term “electroshock” refers to ECT. ECT intentionally induces a controlled seizure under general anesthesia. Conventional rTMS uses targeted magnetic pulses while the patient is awake, without deliberate seizure induction. The treatments differ in their risk profiles, logistics, and clinical indications. NIMH.
6. Can TMS treat anxiety and OCD as well as depression?
Certain TMS devices and protocols have been studied or cleared for conditions beyond MDD, but approval for one indication does not establish efficacy for another. The Hub's TMS for OCD guide covers that separate literature. Anxiety symptoms can coexist with depression and should be assessed in the treatment plan.
7. Do I need an MRI or a brain scan before TMS?
Some individualized targeting protocols use MRI-based or other navigation methods; standard care does not automatically require every patient to have an MRI. The clinic should explain the rationale for the proposed targeting method and whether evidence supports it for the exact stimulation protocol offered. 2025 consensus.
8. What should I do if suicidal thoughts become stronger during treatment?
Tell the treating clinician or another qualified professional immediately and seek urgent evaluation. If there is imminent danger, use emergency services; in the United States, call or text 988. The appearance of worsening suicidal thinking must be addressed as a safety concern and not assumed to be a temporary therapeutic phase. FDA guidance.
XVI. Practical Conclusion
TMS is an established neuromodulation option for selected people with major depression, supported by controlled trials and clinical guidelines. The strongest treatment decision follows a confirmed diagnosis, documented prior care, review of alternatives, protocol-specific safety screening, and a realistic discussion of expected benefit. Standard rTMS and intermittent theta burst have substantial evidence; accelerated approaches are advancing rapidly, with 2026 research strengthening the case for selected protocols while leaving important questions about optimization and durability.
An informed person should leave the consultation knowing which intervention is planned, why it fits their clinical history, how progress will be assessed, the risks and costs, and who will coordinate care afterward. Clinical improvement belongs to the whole treatment journey, including follow-up and prevention of recurrence.
Related Articles
Depression Diagnosis: What a Clinical Evaluation Includes — understanding the assessment that precedes a TMS decision.
Anxiety and Depression: Why They Commonly Co-Occur — assessing overlapping mood and anxiety symptoms.
TMS for OCD: How Transcranial Magnetic Stimulation Works — understanding a different TMS indication.
Childhood Trauma and Depression: Risk, Mechanisms, and Treatment — considering wider contributors to depressive illness.
References
Blumberger, D. M., et al. (2018). Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): A randomised non-inferiority trial. The Lancet, 391, 1683–1692. DOI.
Canadian Network for Mood and Anxiety Treatments (CANMAT), Lam, R. W., et al. (2024). CANMAT 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69, 641–687. DOI.
Centers for Medicare & Medicaid Services. Transcranial Magnetic Stimulation (TMS): Local Coverage Determination L36469. Official coverage database.
Food and Drug Administration. (2011). Repetitive Transcranial Magnetic Stimulation (rTMS) Systems: Class II Special Controls Guidance for Industry and FDA Staff. FDA guidance.
Food and Drug Administration. (2024). NeuroStar Advanced Therapy System, K231926: 510(k) summary and indications for use in adolescents aged 15–21. FDA primary document.
Kishi, T., et al. (2024). Theta burst stimulation for depression: A systematic review and network and pairwise meta-analysis. Molecular Psychiatry. Journal article.
Kratter, I. H., et al. (2026). Stanford neuromodulation therapy for treatment-resistant depression: A randomized controlled trial confirming efficacy, and an EEG study. World Psychiatry, 25, 105–116. DOI.
Mayo Clinic. Transcranial magnetic stimulation: About and what to expect. Clinical procedure guide.
National Institute of Mental Health. Brain stimulation therapies. NIMH.
National Institute of Mental Health. Depression. NIMH.
O'Reardon, J. P., et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biological Psychiatry, 62, 1208–1216. DOI.
Sackeim, H. A., et al. (2020). Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation. Journal of Affective Disorders, 277, 65–74. DOI.
Santos, J. M., et al. (2026). Accelerated intermittent theta-burst stimulation for major depressive episodes: Systematic review and dose-response meta-analysis. Brain Stimulation, 19, 103174. DOI.
Trapp, N. T., et al. (2025). Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology, 170, 206–233. DOI.
Veterans Affairs and Department of Defense. (2022). VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Official guideline.